Prabir Roy-Chaudhury, MD, PhD, FASN, to Become Next President of the American Society of Nephrology

Dr. Roy-Chaudhury will head up an organization—with nearly 21,000 health professionals representing 140 countries—dedicated to leading the fight against kidney diseases.

Preclinical Studies Test Novel Gene Therapy for Treating IgA Nephropathy

IgA nephropathy is an autoimmune kidney disease, and complement, a component of the innate immune system, plays a role in the condition’s pathogenesis. Investigators have developed and tested a novel gene therapy that enters kidney cells and enables them to block complement activation. The research will be presented at ASN Kidney Week 2024 October 23– 27.

Trial Assesses Antibody Therapy for Chronic Active Antibody-Mediated Kidney Transplant Rejection

Chronic active antibody-mediated rejection (caAMR) is a common cause of allograft loss after transplantation, with no approved therapies. Clazakizumab, a monoclonal antibody that targets the inflammatory cytokine interleukin-6 (IL-6), stabilized kidney transplant recipients’ kidney function in a phase 2 trial. Investigators now have data from a phase 3 trial with clazakizumab. The findings from the Phase 3 IMAGINE trial, the largest placebo-controlled study in kidney transplant recipients with caAMR, will be presented at ASN Kidney Week 2024 October 23– 27.

Researchers Test Imlifidase Enzyme Versus Plasma Exchange in Removing Donor-Specific Antibodies in Kidney Transplant Rejection Trial

For kidney transplant recipients experiencing antibody-mediated rejection, the current standard of care involves removing donor-specific antibodies (DSAs) through plasmapheresis (PLEX)—a procedure that removes antibodies from the plasma portion of the blood. Results from a recent clinical trial reveal that an investigational drug called imlifidase, which cleaves and inactivates the type of antibodies that include DSAs, is more effective than PLEX. The research will be presented at ASN Kidney Week 2024 October 23–27.

Do Certain Diabetes Drugs Increase the Risk of Acute Kidney Injury in Patients Taking Anti-Cancer Therapies?

Glucagon-like peptide-1-receptor agonists (GLP-1RA) are medications that are increasingly prescribed for patients with type 2 diabetes and congestive heart failure. Reports of GLP-1RA–associated acute kidney injury (AKI) have emerged, but the risk of GLP-1RA–associated AKI among patients on anti-cancer drugs is unclear. Surprisingly, new research suggests that taking GLP-1RA is not associated with an increased risk of AKI in patients receiving anti-cancer therapies. The findings will be presented at ASN Kidney Week 2024 October 23– 27.

Global, National, and Regional Trends in the Burden of Chronic Kidney Disease among Women

A recent analysis reveals that the number of chronic kidney disease (CKD) cases in women around the globe nearly tripled in the past three decades. Also, type 2 diabetes and hypertension were the leading causes of CKD-related deaths in women. The research will be presented at ASN Kidney Week 2024 October 23– 27.

How the Novel Antibody Felzartamab Impacts IgA Nephropathy

IgA nephropathy (IgAN) is an autoimmune kidney disease driven by immune cells that express a protein called CD38 on their surface. A recent Phase 2 trial revealed that felzartamab, an investigational anti-CD38 monoclonal antibody, helps to reduce proteinuria and maintain patients’ kidney function. Investigators evaluated the molecular mechanisms underlying felzartamab’s potential efficacy in IgAN. The findings will be presented at ASN Kidney Week 2024 October 23– 27.

Heart and Kidney Outcomes After Canagliflozin Treatment in Older Adults

Sodium-glucose co-transporter 2 (SGLT2) inhibitors reduce the risk of cardiovascular and kidney outcomes in patients with type 2 diabetes, but it is unclear whether their effects differ based on patients’ age. A recent analysis of clinical trial data reveals that the SGLT2 inhibitor canagliflozin benefited patients across all age categories. The findings will be presented at ASN Kidney Week 2024 October 23 – 27.

Researchers Integrate Multiple Protein Markers to Predict Health Outcomes in Individuals with Chronic Kidney Disease

Prior efforts to identify novel kidney biomarkers as risk factors for chronic kidney disease (CKD) progression have typically evaluated proteins individually, which limits their prognostic power. The National Institute of Diabetes and Digestive and Kidney Diseases’ (NIDDK’s) CKD Biomarkers Consortium of investigators recently developed and tested novel dimensions of kidney health by combining a set of 17 urine and plasma biomarkers that had been individually associated with CKD progression. The research will be presented at ASN Kidney Week 2024 October 23– 27.

The Clinical Significance of Microvascular Inflammation after Kidney Transplantation

Investigators recently uncovered key insights into newly defined rejection entities in kidney transplantation that may offer improved patient risk categorization post-transplant. The research will be presented at ASN Kidney Week 2024 October 23– 27.

Researchers Create New System to Decode Genetic Risk for Psychiatric Disorders

The lab of Jason Stein, PhD, associate professor of genetics and member of the UNC Neuroscience Center, has created a controlled model system that could help researchers know more about the genetic variants that increase one’s risk for developing a psychiatric disorder.

Genomic treasure trove: Vernicia montana’s DNA unearths new breeding horizons

A pioneering study has unveiled the genetic blueprint of Vernicia montana, a plant renowned for its high-value tung oil and ornamental beauty. The research decodes its chromosome-level genome, providing unparalleled insights into its evolution and setting the stage for advanced molecular breeding and sex identification methods.

Bulwark of blooms: the lily’s secret armor against plant pathogens

A cutting-edge study reveals the biochemical defense system of the wild lily, Lilium regale, which demonstrates remarkable resistance against Fusarium wilt—a major threat to the floriculture industry. The research uncovers the lily’s robust defense mechanisms, spotlighting the critical role of phenylpropanoid metabolism and the regulatory influence of specific transcription factors. These findings offer valuable insights for developing crops with enhanced disease resistance.

From kale to carotenoid powerhouse: a breakthrough in plant nutrition

A recent study has identified a crucial regulatory mechanism in Chinese kale, potentially revolutionizing its nutritional profile. By manipulating the BoaBZR1.1 transcription factor, researchers significantly enhanced carotenoid levels, crucial antioxidants for human health. This advancement opens pathways for improving vegetable nutrition through genetic engineering.

A genetic predisposition to alcohol use is not the same as a genetic destiny for alcohol misuse

There is a clear relationship between alcohol and neurodegeneration; for example, an alcohol use disorder correlates with a higher risk of Alzheimer’s disease. It is unclear, however, whether individual differences in brain structure and connectivity are risk factors for, or consequences of, alcohol use. New research exploring this relationship will be shared on Wednesday, 26 June 2024 at the 47th annual scientific meeting of the Research Society on Alcohol (RSA) in Minneapolis, Minnesota.

Biotech entrepreneur donates $50 million to UC Irvine School of Biological Sciences

The University of California, Irvine has received a $50 million donation from Orange County biotech entrepreneur Charlie Dunlop for the School of Biological Sciences. Dean Frank LaFerla announced the gift before thousands of graduating students, faculty and family supporters at today’s school commencement, where Dunlop was the featured speaker.

New AI Tool Finds Rare Variants Linked to Heart Disease in 17 Genes

Using an advanced artificial intelligence tool, researchers at the Icahn School of Medicine at Mount Sinai have identified rare coding variants in 17 genes that shed light on the molecular basis of coronary artery disease (CAD), the leading cause of morbidity and mortality worldwide. The discoveries, detailed in the June 11 online issue of Nature Genetics, reveal genetic factors impacting heart disease that open new avenues for targeted treatments and personalized approaches to cardiovascular care. The investigators used an in silico, or computer-derived, score for coronary artery disease (ISCAD) that holistically represents CAD, as described in a previous paper by the team in The Lancet. The ISCAD score incorporates hundreds of different clinical features from the electronic health record, including vital signs, laboratory test results, medications, symptoms, and diagnoses. To build the score, they trained machine learning models on the electronic health records of 604,914 individuals

Mount Sinai Study Identifies Genetic Link Between Inflammatory Bowel Disease and Parkinson’s Disease

Researchers at the Icahn School of Medicine at Mount Sinai have made a significant discovery, identifying genetic connections between inflammatory bowel disease (IBD) and Parkinson’s disease (PD). Published in Genome Medicine on May 13, their study highlights the potential for joint therapeutic strategies to target these two challenging disorders.

UC Irvine-led research team builds first tandem repeat expansions genetic reference maps

A research team led by the University of California, Irvine has built the first genetic reference maps for short lengths of DNA repeated multiple times which are known to cause more than 50 lethal human diseases, including amyotrophic lateral sclerosis, Huntington’s disease and multiple cancers.